Enzo Biochem (NYSE:ENZ) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report released on Saturday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Down 1.4 %

Shares of Enzo Biochem stock opened at $0.66 on Friday. Enzo Biochem has a 12-month low of $0.63 and a 12-month high of $1.44. The stock’s fifty day moving average is $0.88 and its 200-day moving average is $1.04.

Enzo Biochem (NYSE:ENZ) last announced its earnings results on Monday, December 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Enzo Biochem Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were given a dividend of $0.10 per share. This represents a $0.40 annualized dividend and a yield of 60.98%. The ex-dividend date was Friday, November 15th.

Institutional Investors Weigh In On Enzo Biochem

A number of institutional investors have recently bought and sold shares of the business. BBR Partners LLC acquired a new stake in shares of Enzo Biochem during the third quarter worth approximately $112,000. Renaissance Technologies LLC lifted its position in Enzo Biochem by 2.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after buying an additional 64,417 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after buying an additional 13,735 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 11,742 shares in the last quarter. 36.90% of the stock is currently owned by institutional investors and hedge funds.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.